Avalo Therapeutics, Inc. – NASDAQ:AVTX

Avalo Therapeutics stock price today

$8.9
+0.57
+6.84%
Financial Health
0
1
2
3
4
5
6
7
8
9

Avalo Therapeutics stock price monthly change

-31.50%
month

Avalo Therapeutics stock price quarterly change

-31.50%
quarter

Avalo Therapeutics stock price yearly change

+15919.23%
year

Avalo Therapeutics key metrics

Market Cap
90.98M
Enterprise value
32.50M
P/E
-0.54
EV/Sales
1.60
EV/EBITDA
-0.44
Price/Sales
1.29
Price/Book
-2.40
PEG ratio
-0.01
EPS
-318.9
Revenue
N/A
EBITDA
-19.98M
Income
-142.87M
Revenue Q/Q
-100%
Revenue Y/Y
-91.64%
Profit margin
-378.61%
Oper. margin
-366.98%
Gross margin
71.76%
EBIT margin
-366.98%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Avalo Therapeutics stock price history

Avalo Therapeutics stock forecast

Avalo Therapeutics financial statements

Avalo Therapeutics, Inc. (NASDAQ:AVTX): Profit margin
Jun 2023 643K -8.19M -1274.18%
Sep 2023 236K -5.22M -2215.25%
Dec 2023 571K -8.16M -1430.47%
Mar 2024 0 -121.29M
Avalo Therapeutics, Inc. (NASDAQ:AVTX): Analyst Estimates
2025 1M -36M -3600%
2026 1M -39M -3900%
2027 1M -313.83K -31.38%
2028 1.70M -341.60K -20.03%
  • Analysts Price target

  • Financials & Ratios estimates

Avalo Therapeutics, Inc. (NASDAQ:AVTX): Debt to assets
Jun 2023 24235000 31.20M 128.76%
Sep 2023 29270000 14.57M 49.8%
Dec 2023 20993000 13.68M 65.21%
Mar 2024 123728000 224.81M 181.7%
Avalo Therapeutics, Inc. (NASDAQ:AVTX): Cash Flow
Jun 2023 -11.02M 158K 598K
Sep 2023 -6.83M 0 10.69M
Dec 2023 -2.76M -158K 1K
Mar 2024 -6.20M 356K 108.61M

Avalo Therapeutics alternative data

Avalo Therapeutics, Inc. (NASDAQ:AVTX): Employee count
Sep 2023 20
Oct 2023 20
Nov 2023 20
Dec 2023 20
Jan 2024 20
Feb 2024 20
Mar 2024 20
Apr 2024 20
May 2024 19
Jun 2024 19
Jul 2024 19

Avalo Therapeutics other data

2.18% -97.82%
of AVTX is owned by hedge funds
205.43K -5.34M
shares is hold by hedge funds

Avalo Therapeutics, Inc. (NASDAQ:AVTX): Insider trades (number of shares)
Period Buy Sel
Dec 2022 2083 0
Feb 2023 900000 0
Apr 2023 106329 0
May 2023 68515 0
Jun 2023 1651996 3683542
Transaction Date Insider Security Shares Price per share Total value Source
Sale
ARMISTICE CAPITAL, LLC 10 percent owner
Common Stock 937,404 $0.52 $486,513
Sale
ARMISTICE CAPITAL, LLC 10 percent owner
Common Stock 2,746,138 $0.61 $1,683,383
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 1,608,000 $0.63 $1,016,256
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 2,000 $4.14 $8,288
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 3,000 $3.91 $11,715
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 3,160 $3.68 $11,641
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 6,000 $3.48 $20,874
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 8,750 $3.82 $33,443
Purchase
CAISSA CAPITAL MANAGEMENT LTD. 10 percent owner
Common Stock 2,149 $4.34 $9,316
Purchase
SULLIVAN CHRISTOPHER RYAN officer: Chief Fi.. Common Stock 511 $3.42 $1,748
Tuesday, 12 November 2024
globenewswire.com
Monday, 11 November 2024
globenewswire.com
Tuesday, 8 October 2024
globenewswire.com
Wednesday, 24 July 2024
investorplace.com
Tuesday, 16 July 2024
globenewswire.com
Tuesday, 9 July 2024
globenewswire.com
Monday, 24 June 2024
globenewswire.com
Monday, 17 June 2024
globenewswire.com
Wednesday, 22 May 2024
zacks.com
Monday, 13 May 2024
globenewswire.com
Tuesday, 2 April 2024
Zacks Investment Research
Monday, 1 April 2024
Invezz
Thursday, 28 March 2024
InvestorPlace
Wednesday, 27 March 2024
Zacks Investment Research
Wednesday, 3 January 2024
Zacks Investment Research
Thursday, 14 December 2023
Zacks Investment Research
Monday, 27 November 2023
Zacks Investment Research
Tuesday, 21 November 2023
Zacks Investment Research
Thursday, 12 October 2023
Invezz
Thursday, 21 September 2023
PennyStocks
Tuesday, 19 September 2023
PennyStocks
Wednesday, 13 September 2023
Zacks Investment Research
Wednesday, 6 September 2023
GlobeNewsWire
Friday, 18 August 2023
InvestorPlace
Tuesday, 27 June 2023
Zacks Investment Research
Thursday, 1 June 2023
GlobeNewsWire
Monday, 15 May 2023
GlobeNewsWire
Wednesday, 10 May 2023
GlobeNewsWire
Thursday, 4 May 2023
Zacks Investment Research
Tuesday, 25 April 2023
InvestorPlace
  • What's the price of Avalo Therapeutics stock today?

    One share of Avalo Therapeutics stock can currently be purchased for approximately $8.9.

  • When is Avalo Therapeutics's next earnings date?

    Unfortunately, Avalo Therapeutics's (AVTX) next earnings date is currently unknown.

  • Does Avalo Therapeutics pay dividends?

    No, Avalo Therapeutics does not pay dividends.

  • How much money does Avalo Therapeutics make?

    Avalo Therapeutics has a market capitalization of 90.98M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 89.34% to 1.92M US dollars.

  • What is Avalo Therapeutics's stock symbol?

    Avalo Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AVTX".

  • What is Avalo Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Avalo Therapeutics?

    Shares of Avalo Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Avalo Therapeutics's key executives?

    Avalo Therapeutics's management team includes the following people:

    • Dr. Garry A. Neil M.D. Chief Scientific Officer(age: 71, pay: $705,480)
    • Dr. H. Jeffery Wilkins M.D. Chief Medical Officer(age: 63, pay: $547,420)
    • Mr. Michael F. Cola Chief Executive Officer & Director(age: 65, pay: $464,990)
  • How many employees does Avalo Therapeutics have?

    As Jul 2024, Avalo Therapeutics employs 19 workers, which is 5% less then previous quarter.

  • When Avalo Therapeutics went public?

    Avalo Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 14 Oct 2015.

  • What is Avalo Therapeutics's official website?

    The official website for Avalo Therapeutics is avalotx.com.

  • Where are Avalo Therapeutics's headquarters?

    Avalo Therapeutics is headquartered at 540 Gaither Road, Rockville, MD.

  • How can i contact Avalo Therapeutics?

    Avalo Therapeutics's mailing address is 540 Gaither Road, Rockville, MD and company can be reached via phone at +41 05228707.

Avalo Therapeutics company profile:

Avalo Therapeutics, Inc.

avalotx.com
Exchange:

NASDAQ

Full time employees:

19

Industry:

Biotechnology

Sector:

Healthcare

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

540 Gaither Road
Rockville, MD 20850

CIK: 0001534120
ISIN: US05338F3064
CUSIP: 05338F108